Sign In
Last checked at 
5 May 2022 07:00
5 May 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Contract win
US$1m+ contract with global pharma company for data feed from the DXRX platform
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce it has secured a five-year, multi-product subscription contract with a top 30 global pharma company, to deliver customised data insights via the DXRX platform. The total contract value is in excess of $1m spread across five years and subject to certain milestones, significantly expanding Diaceutics' existing relationship with the company and setting Diaceutics up for future opportunities with the client.
The contract will see Diaceutics deliver a core set of real-world data and insights on lab test results that identify physicians who are treating patients in their target cohorts. The demand for biomarker test results and interpretation customised to the client's needs in oncology was a key value proposition for DXRX Signal, one of the primary products being taken.
This contract further demonstrates the applicability and demand for new products enabled by the DXRX platform and supports the move towards enhanced multi-year recurring revenues, a key strategy for the Company going forward.
Ryan Keeling, CIO and Co-Founder of Diaceutics PLC, commented:
"This multi-product, multi-year auto renew contract speaks to how our DXRX platform spans the full diagnostic commercialisation pathway; in this instance providing our client with the insights they need to better engage with prescribers to choose their therapy.
"We are encouraged by the pace of deal flow for our newly launched data feeds, which are proving valuable entry points for both new and existing customers onto the DXRX platform."
Enquiries:
Diaceutics PLC |
|
Nick Roberts, Chief Financial Officer | Via Alma PR |
Ryan Keeling, Chief Innovation Officer |
|
|
|
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison, Stewart Wallace, Nick Adams |
|
|
|
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde, Kieran Breheny, Matthew Young | diaceutics@almapr.co.uk |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.
Follow the stocks
